Latest Conference Articles

June 7th 2021, 1:00pm

ASCO Annual Meeting

The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

June 7th 2021, 12:00pm

ASCO Annual Meeting

Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

June 6th 2021, 8:00pm

ASCO Annual Meeting

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

June 6th 2021, 7:00pm

ASCO Annual Meeting

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

June 6th 2021, 5:00pm

ASCO Annual Meeting

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

June 5th 2021, 3:00pm

ASCO Annual Meeting

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

June 5th 2021, 1:00pm

ASCO Annual Meeting

The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.

April 30th 2021, 3:22pm

Extraordinary Healer® Award for Oncology Nursing

View the entire 2021 Extraordinary Healer® Award for Oncology Nursing virtual presentation here!

March 16th 2021, 1:00pm

Educated Patient® Breast Cancer Summit

An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.

March 15th 2021, 1:00pm

Educated Patient® Lung Cancer Summit

In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.